

Optimizing Bone Health in Cancer Patients

Jane M. Pruemmer, Pharm.D., BCOP, FASHP
Professor Of Clinical Pharmacy Practice and
Oncology Clinical Pharmacy Specialist
James L. Winkle College of Pharmacy
University of Cincinnati
Barrett Cancer Center and University Hospital
UC Health
Cincinnati, Ohio


Planned and conducted by ASHP Advantage.
Supported by an educational grant from Novartis Oncology.



Disclosures for Faculty and Planners

- Chad Barnett, Pharm.D., BCOP, Initiative Co-chair
 - No pertinent relationships to report
- Jane Pruemmer, Pharm.D., BCOP, FASHP, Initiative Co-chair
 - No pertinent relationships to report
- Erika Thomas, M.B.A., B.S.Pharm., Staff
 - No pertinent relationships to report


Learning Objectives




- Describe the prevalence, morbidity, mortality, and impact on quality of life of skeletal-related events in patients with cancer.
- Explain normal bone remodeling and the pathogenesis of skeletal-related events in patients with cancer.
- Discuss the mechanism of action, efficacy, and safety of agents used for treating bone metastases and slowing or preventing cancer treatment-induced bone loss (CTIBL).
- Recommend a pharmacologic regimen for a patient with bone metastases or CTIBL.
- Identify new or emerging bone-targeted therapies for patients with bone metastases and describe mechanisms of action and potential roles in improving bone health in cancer patients.

Bone Health in Cancer Patients

- **Background**
- *Cancer Treatment-Induced Bone Loss*
- *Bone metastases*
- *Adjuvant bisphosphonates*
- *New and emerging bone-targeted therapies*




Bone Disease



- Osteoporosis
 - Postmenopausal
 - Aging
 - Hypogonadal states
 - Drug-induced
- Cancer-related bone loss
- Cancer therapy–related bone loss
- Bone metastases
 - Estimated 350,000 deaths per year from bone metastases


Bone Remodeling in Healthy Individuals



Deal C. Nat Clin Pract Rheumatol. 2009;5:20. Nature clinical practice rheumatology by NATURE PUBLISHING GROUP. Reproduced with permission of NATURE PUBLISHING GROUP in the format Journal via Copyright Clearance Center.

Bone Health in Cancer Patients

- *Background*
- **Cancer Treatment-Induced Bone Loss**
- *Bone metastases*
- *Adjuvant bisphosphonates*
- *New and emerging bone-targeted therapies*



Patient case #1 - JK

- 64 y.o. postmenopausal white female
- Newly diagnosed right breast cancer
 - T = 0.5 x 0.4 cm; N0 (US), ER/PR+, HER2 negative by IHC
- Underwent segmental mastectomy and sentinel LN biopsy
- Completed radiation and started anastrozole 1 mg PO daily
- Baseline BMD by DEXA scan:

Region	BMD (g/cm ²)	T-score	Classification
AP spine	0.830	-2.0	Osteopenic
Femoral neck (left)	0.631	-2.0	Osteopenic
Total hip (left)	0.775	-1.4	Osteopenic
Femoral neck (right)	0.673	-1.6	Osteopenic
Total hip (right)	0.819	-0.6	Normal

BMD, bone mineral density; DEXA, dual –energy x-ray absorptiometry.

Question #1

Which of the following medications is most appropriate for prevention of aromatase inhibitor (AI)-induced bone loss in our patient?

1. Teriparatide
2. Raloxifene
3. Alendronate
4. Conjugated estrogen


Cancer Treatment–Induced Bone Loss

- Rapid and severe bone loss resulting from cancer therapies that lead to estrogen or androgen deprivation
- Various cancer therapies decrease BMD and increase fracture risk
 - Androgen-deprivation therapy (ADT)
 - Estrogen-deprivation therapy
 - Chemotherapy
 - Surgical (castration)
- CTIBL has significant clinical, social, and economic consequences; treatment-related fractures are associated with decreased quality of life and shorter survival

Coleman RE. *Cancer* 1997;80(8Suppl):1588.

Coleman RE and McCloskey EV. *Bone*. 2011 Feb 18. [Epub ahead of print].

The Vicious Cycle in the Bone Microenvironment




Diagnostic Categories of Bone Mineral Density (T-score)

Diagnostic Category	WHO Criterion-BMD or BMC
Normal	$< 1.0 \text{ SD}^*$
Osteopenia	$> 1.0 \text{ but } < 2.5 \text{ SD}^*$
Osteoporosis	$\geq 2.5 \text{ SD}^*$
Severe osteoporosis	$\geq 2.5 \text{ SD}^* + \geq 1 \text{ fragility fracture(s)}$

BMD, bone mineral density; BMC, bone mineral content; SD, standard deviation.

* Compared to reference mean for young adults

Bone Loss With Cancer Therapies




1. Kanis JA. Osteoporosis. 1997;22-55. 2. Eastell R, et al. J Bone Mineral Res. 2002. 3. Mailefert JF, et al. J Urol. 1999;161:1219-1222. 4. Gnant M, et al. Lancet Oncol. 2008;9:840-849. 5. Shapiro CL, et al. J Clin Oncol. 2001;19:3306-3311.

Endocrine Therapies Associated with Bone Loss

- LHRH agonists
 - Goserelin
 - Leuprolide
 - Triptorelin
 - Histrelin
 - Nafarelin
- LHRH antagonists
 - Degarelix
- Aromatase inhibitors
 - Anastrozole
 - Letrozole
 - Exemestane

LHRH = luteinizing hormone-releasing hormone

Aromatase Inhibitors (AI) Increase Fracture Risk Compared With Tamoxifen



1. Buzdar A, et al. Lancet Oncol. 2006;7(8):633-43. 2. Coombes RC, et al. Lancet. 2007; 369(9561):559-70. 3. Rabaglio M, et al. Ann Oncol. 2009; 20(9):1489-98. 4. Goss PE, et al. J Natl Cancer Inst. 2005; 97:1262-1271.

FDA-Approved Agents for Prevention or Treatment of Osteoporosis

Drug	Dose
Alendronate	10 mg/day or 70 mg/week po
Risedronate	5 mg/day or 35 mg/week po
Ibandronate	2.5 mg/day or 150 mg/month po or 3 mg IV every 3 months
Zoledronic acid	5 mg IV every 12 months
Raloxifene	60 mg/day po
Estrogen	Variable doses and routes
Calcitonin	200 international units/day IV
Denosumab	60 mg SQ every 6 months
Teriparatide	20 mcg/day subcutaneously

Important Distinctions Between Osteoporosis and SRE Dosing

Medication	Osteoporosis	Prevention of SREs
Zoledronic acid	Reclast [®] 5 mg IV every 12 months	Zometa [®] 4 mg IV every 3-4 weeks
Denosumab	Prolia [™] 60 mg SC every 6 months	Xgeva [™] 120 mg SC every 4 weeks

IV = intravenous, SC = subcutaneous

Prolia[™] product information. Amgen, Inc, Thousand Oaks, CA; 2010;

Reclast[®] product information. Novartis Pharmaceuticals, East Hanover, NJ; March 2011;


Xgeva[™] product information. Amgen, Inc, Thousand Oaks, CA; November 2010;

Zometa[®] product information. Novartis Pharmaceuticals, East Hanover, NJ; February 2011.

Bisphosphonate: Mechanism of Action

- Diminish bone resorption and subsequently normalize calcium levels
 - Inhibits osteoclastic activity and induces osteoclast apoptosis
 - Prevents development of new osteolytic lesions
 - The newer agents act by inhibiting specific enzymes in the mevalonate pathway of cholesterol biosynthesis in osteoclasts, which in turn leads to impaired prenylation of small GTP-binding proteins

Mechanism of Action of Bisphosphonates




Deal C. Nat Clin Pract Rheumatol. 2009;5:20. Nature clinical practice rheumatology by NATURE PUBLISHING GROUP. Reproduced with permission of NATURE PUBLISHING GROUP in the format Journal via Copyright Clearance Center.

Bisphosphonate Toxicities

- Common
 - Nausea
 - Fatigue
 - Anemia
 - Bone pain
 - Constipation
 - Fever
 - Vomiting
 - Dyspnea
- Less common, but serious
 - Renal toxicity
 - Osteonecrosis of the jaw
- Rare
 - Femoral stress fractures

RANK/RANK-L/Osteoprotegerin Pathway




Adapted from Bartsch R, Steger GG. *Expert Opin Biol Ther.* 2009; 9:1225.

Denosumab

- First monoclonal antibody to RANKL
- Fully human monoclonal immunoglobulin G (IgG2) antibody
- 60 mg subcutaneously every 6 months, with calcium and Vitamin D
- Rapid onset of inhibition of bone turnover

Miller PD. *Best Pract Res Clin Endocrin Metab.* 2008; 22:849.
Burkiewicz JS et al. *Ann Pharmacother.* 2009; 43:1445.

Mechanism of Action of Denosumab



Deal C. Nat Clin Pract Rheumatol. 2009;5:20. Nature clinical practice rheumatology by NATURE PUBLISHING GROUP. Reproduced with permission of NATURE PUBLISHING GROUP in the format Journal via Copyright Clearance Center.

Denosumab: Adverse Events

- Common
 - Arthralgias
 - Back pain
 - Bone pain
 - Dermatitis, rash
 - Fatigue
 - Headache
 - Nasopharyngitis
- Less Common, but serious
 - Skin infections
 - Hypocalcemia
 - Hypophosphatemia
 - Hyperphosphatemia
 - Osteonecrosis of the jaw

Estrogens

- Antiresorptive agents that inhibit bone resorption, increase bone mineral density, and reduce the risk for both vertebral and hip fractures
- Works through the RANK pathway
- The best prospective fracture data come from the Women's Health Initiative (WHI) study
 - Reduces the risk of fractures by 24%
- Safety issues
 - Increased risk of breast cancer, stroke, or DVT/VTEs

Selective Estrogen Receptor Modulators (SERMs): Raloxifene

- Share agonist and antagonistic mechanisms of action with the estrogen receptor
- Agonistic to the bone; antagonistic to the ER on breast and uterine tissue
- MORE trial demonstrated that 60 mg/day of oral raloxifene reduced the incidence of vertebral fractures in women
- Potential negative effect when combined with endocrine therapy for breast cancer
- Concerns for VTE

Calcitonin

- A peptide derived from the parafollicular cells of the thyroid (salmon or human synthetic)
- An inhibitor of osteoclast activity
- 100 international units/day injectable or 200 international units/day nasal spray
- Nausea with the injectable formula
- Rhinitis with nasal spray
- Allergic reactions with salmon derivative
- ASCO Guideline on Bone Health Issues in Women with Breast Cancer indicates no issues with calcitonin, but not highly recommended

Teriparatide

- Recombinant human parathyroid hormone
- FDA-approved for use in men and postmenopausal women with osteoporosis who are at high risk for fractures
- Directly stimulates bone formation by increasing the production of bone matrix by osteoblasts and reversing microarchitectural deterioration
- ASCO guidelines do not recommend it for use in women with breast cancer due to increased risk of osteosarcomas in animals

Thomas T. *Joint Bone Spine*. 2006; 73:262.
Hillner BE, et al. *J Clin Oncol* 2003; 21:4042.

Question #1

Which of the following medications is most appropriate for prevention of AI-induced bone loss in our patient?

1. Teriparatide
2. Raloxifene
3. Alendronate
4. Conjugated estrogen

Oral Bisphosphonates for Prevention of AI-Associated Bone Loss in Breast Cancer Patients with an Intermediate Risk of Fracture

Bisphos	% change in spine BMD		P-value	% change in hip BMD		P-value
	Bisphos	No bisphos		Bisphos	No bisphos	
Risedronate 35 mg ¹	+5.7	-1.5	0.006	+1.6	-3.9	0.037
Risedronate 35 mg ²	+2.2	-1.8	<0.0001	+1.8	-1.1	<0.0001
Ibandronate 150 mg ³	+2.98	-3.22	<0.01	+0.6	-3.90	<0.01

¹Markopoulos C, et al. *Breast Cancer Res.* 2010; 12(2):R24. Epub 2010 Apr 16.

²Van Poznak C, et al. *J Clin Oncol.* 2010; 28(6):967-75.

³Lester JE, et al. *Clin Cancer Res.* 2008; 14(19):6336-42.

Oral Bisphosphonates for Prevention of ADT-Associated Bone Loss in Prostate Cancer Patients


Bisphos	% change in spine BMD		P-value	% change in hip BMD		P-value
	Bisphos	No bisphos		Bisphos	No bisphos	
Alendronate 70 mg wkly ¹	+3.7	-1.4	<0.001	+0.7	-0.7	0.002

Greenspan SL, et al. *Ann Intern Med.* 2007; 146(6):416-24.

Zoledronic Acid for Prevention of AI-Associated Bone Loss in Breast Cancer Patients

- Premenopausal
 - ABCSG-12 bone substudy (n = 404)
- Postmenopausal
 - Z-FAST (N = 602)
 - ZO-FAST (N = 1065)
 - E-ZO-FAST (N = 527)


ABCESG-12 Bone Sub-study



Time	% change in spine BMD		P-value	% change in hip BMD		P-value
	ZOL	No ZOL		ZOL	No ZOL	
12 mo	+1.5	-7.4	<0.0001	+0.8	-4.1	0.010
36 mo	+0.4	-11.3	<0.0001	+0.8	-7.3	<0.0001
60 mo	+4.0	-6.3	0.001	+3.9	-4.1	0.058

Gnant M, et al. *Lancet Oncol.* 2008;9(9):840-9.


Z/ZO-FAST Trial Design



Brufsky AM, et al. *Clin Breast Cancer*. 2009;9(2):77-85.
Eidtmann H, et al. *Ann Oncol*. 2010;21(11):2188-94.

Immediate vs Delayed ZA


Mean % Change in BMD From Baseline to 36 Mos



Brufsky AM, et al. *Clin Breast Cancer*. 2009;9(2):77-85.
Eidtmann H, et al. *Ann Oncol*. 2010;21(11):2188-94.

Immediate vs Delayed ZA

Incidence of Fractures



Brufsky AM, et al. *Clin Breast Cancer*. 2009; 9(2):77-85.

Eidtmann H, et al. *Ann Oncol*. 2010; 21(11):2188-94.

IV Bisphosphonates for Prevention of ADT-Associated Bone Loss in Prostate Cancer Patients

Bisphos	% change in spine BMD		P-value	% change in hip BMD		P-value
	Bisphos	No bisphos		Bisphos	No bisphos	
Pamidronate ¹	+0.5	-3.3	<0.001	+0.2	-1.8	0.005
Zoledronic acid ²	+5.6	-2.2	<0.001	+1.1	-2.8	<0.001
Zoledronic acid ³	+4.0	-3.1	<0.001	+0.7	-1.9	0.004
Zoledronic acid ⁴	+3.3	-1.5	<0.01	+0.9	-2.0	<0.01

¹Smith MR, et al. *N Engl J Med*. 2001; 345(13):948-55.

²Smith MR, et al. *J Urol*. 2003; 169(6):2008-12.

³Michaelson MD, et al. *J Clin Oncol*. 2007; 25(9):1038-42.

⁴Casey R, et al. *Can J Urol*. 2010; 17(3):5170-7.

Denosumab in patients with CTIBL

	Denosumab	Placebo	P-value
Breast cancer patients receiving an AI (n=252)			
% change in LS BMD	+4.8%	-0.7%	<0.0001
Prostate cancer patients receiving ADT (n=1468)			
% change in LS BMD	+5.6%	-1.0%	<0.001

- No difference in fracture incidence in breast cancer study
- Decrease incidence of new vertebral fractures at 36 mo with denosumab vs placebo group (1.5% vs 3.9%, $p=0.006$) in prostate cancer study

Ellis GK, et al. *J Clin Oncol*. 2008; 26(30):4875-82.
Smith MR, et al. *N Engl J Med*. 2009; 361(8):745-55.

Patient case #1 - JK


- 64 y.o. postmenopausal white female with newly diagnosed right breast cancer
- Underwent surgery, radiation and started anastrozole
- Baseline BMD by DEXA scan:
 - Osteopenia in spine, left and right femoral neck, left total hip
 - Normal right total hip
- Promote lifestyle changes
- Recommend calcium and vitamin D
 - Assessment of vitamin D levels may be reasonable
- Consider starting an oral bisphosphonate
 - Alendronate, risedronate, or ibandronate
- Monitor BMD by DEXA scan yearly

CTIBL Summary

- Cancer patients may be at increased risk for bone loss and fracture due to specific cancer treatments
- Patients at risk for CTIBL should be assessed for bone loss risk
- Bisphosphonates are the preferred agents for prevention and treatment of CTIBL
- Some data with denosumab for CTIBL
 - May be an option in patients refractory to bisphosphonates?

Bone Health in Cancer Patients

- *Background*
- *Cancer Treatment-Induced Bone Loss*
- **Bone metastases**
- *Adjuvant bisphosphonates*
- *New and emerging bone-targeted therapies*



Patient case #2


- RR is a 75 year old Caucasian man with newly recurrent prostate cancer which is metastatic to the bones
- Current PSA is 143 and bone scan shows involvement of both femurs and lumbosacral vertebrae
- RR had originally been treated 3 years ago with external beam radiation and brachytherapy with radiation seed implants
- He is now receiving leuprolide 3-month injections

Question #2


In our patient, which of the following medications would be appropriate for reduction of skeletal-related events (SRE)?

1. Zoledronic acid or pamidronate
2. Denosumab and pamidronate
3. Pamidronate
4. Zoledronic acid or denosumab

Skeletal-Related Events (SRE) Associated with Bone Metastases


- Pathological fractures
 - Nonvertebral
 - Vertebral compression
 - Spinal cord compression/collapse
 - Radiation therapy
 - Surgery to bone
 - Hypercalcemia
 - Not included in some studies
- 
- SREs

Prevalence of SREs in Patients with Metastatic Breast Cancer




Lipton A, et al. Cancer. 2000; 88(5):1082-90

Development of Bone Metastases




Reprinted by permission from Macmillan Publishers Ltd: *Nat Rev Cancer* (Mundy GR. *Nat Rev Cancer*. 2002; 2:584), copyright 2002.

Osteolytic Bone Metastases




Reprinted by permission from Macmillan Publishers Ltd: *Nat Rev Cancer* (Mundy GR. *Nat Rev Cancer*. 2002; 2:584), copyright 2002.


RANK-RANKL System in Osteolytic Bone Metastases



Osteoblastic Bone Metastases



IV Bisphosphonates in Solid Tumors- Selected RCT



Small EJ, et al. *J Clin Oncol.* 2003; 21(23):4277-84. Saad F, et al. *J Natl Cancer Inst.* 2004; 96(11):879-82. Rosen LS, et al. *Cancer.* 2004; 100(12):2613-21. Lipton A, et al. *Cancer.* 2000;88(5):1082-90. Body JJ, et al. *Ann Oncol.* 2003; 14(9): 1399-405. Rosen LS, et al. *Cancer.* 2004; 100(1):36-43.

Denosumab vs Zoledronate in Patients with Bone Metastases

	Denosumab	Zoledronic acid	HR (95% CI)	P-value (noninferiority)
Breast cancer (n=2046)				
Median time to first SRE	Not reached	26.4 mo	0.82 (0.71-0.95)	<0.001 ¹
Solid tumors (other than breast and prostate) and multiple myeloma (n=1776)				
Median time to first SRE	20.5 mo	16.3 mo	0.84 (0.71- 0.98)	<0.001 ²
Castrate-resistant prostate cancer (n=1901)				
Median time to first SRE	20.7 mo	17.1 mo	0.82 (0.71- 0.95)	<0.001 ³

¹p=0.01 (superiority), ²p=0.06 (superiority), ³p=0.008 (superiority)

Xgeva™ product information. Amgen, Inc, Thousand Oaks, CA; November 2010.

Reduction of SREs in Solid Tumors: Remaining Questions

- **Optimal length of treatment?**
 - Little data available beyond 2 years of tx
- **Optimal dosing interval of bisphosphonates?**
 - Monthly vs every 3 months
 - Trials ongoing – OPTIMIZE 2, CALGB 70604
- **Bisphosphonates or denosumab?**
 - Concerns regarding long-term toxicities with denosumab?
 - Cost/economics


Question #2

In our patient, which of the following medications would be appropriate for reduction of SREs?

1. Zoledronic acid or pamidronate
2. Denosumab and pamidronate
3. Pamidronate
4. Zoledronic acid or denosumab

Bone Health in Cancer Patients

- *Background*
- *Cancer Treatment-Induced Bone Loss*
- *Bone metastases*
- **Adjuvant bisphosphonates**
- *New and emerging bone-targeted therapies*



Patient case #3 - JK

- 64 y.o. postmenopausal white female with newly diagnosed right breast cancer
- Currently taking calcium/vitamin D, alendronate, and anastrozole
- Patient calls clinic to inquire about anti-cancer effects of bisphosphonates

Question #3

Based on the results from the AZURE trial,
your response is:

1. Adjuvant bisphosphonates resulted in worse disease-free survival
2. Adjuvant bisphosphonates improved disease-free survival
3. Risk of ONJ was increased with adjuvant bisphosphonates
4. Adjuvant bisphosphonates increase the risk of neutropenia compared to placebo

Adjuvant Zoledronic Acid

ABCSG XII


36% reduction in
risk of disease
progression

ZO-FAST

41% reduction in
disease-free
survival events


Gnant M, et al. *N Engl J Med*. 2009; 360(7):679-91.
Eidtmann H, et al. *Ann Oncol*. 2010; 21(11):2188-94.

AZURE Study Design



Coleman RE, et al. SABCS 2010; S4-5.

Standard Therapy +/- Zoledronate



DFS , disease-free survival; IDFS, invasive disease-free survival.

Standard Therapy +/- Zoledronate Toxicity

	Control Group	Zoledronic Acid Group
Adverse Event	Number (%)	Number (%)
Neutropenic sepsis	159 (9.5)	159 (9.5)
Neutropenia	49 (2.9)	41 (2.5)
Pyrexia	24 (1.4)	37 (2.2)
Vomiting	23 (1.4)	35 (2.1)
Lower Respiratory Infection	33 (2.0)	24 (1.4)
Central line infection	21 (1.3)	24 (1.4)
Cellulitis	21 (1.3)	21 (1.3)
Pulmonary embolus	13 (0.8)	25 (1.5)
Confirmed ONJ	0	17*
Possible ONJ	0	9

*p<0.0001

Adjuvant Bisphosphonates

Conclusions

- Antitumor results preliminary at this time
 - No difference in DFS or OS in AZURE study
 - Awaiting further results of these and other trials
 - NSABP B34
 - SWOG 0307
 - Adjuvant denosumab?
- Must consider adverse events from agents
 - Osteonecrosis of the jaw
 - Acute inflammatory response
 - Musculoskeletal pain


Question #3

Based on the results from the AZURE trial, your response is:

1. Adjuvant bisphosphonates resulted in worse disease-free survival
2. Adjuvant bisphosphonates improved disease-free survival
3. Risk of ONJ was increased with adjuvant bisphosphonates
4. Adjuvant bisphosphonates increase the risk of neutropenia compared to placebo

Bone Health in Cancer Patients

- *Background*
- *Cancer Treatment-Induced Bone Loss*
- *Bone metastases*
- *Adjuvant bisphosphonates*
- **New and emerging bone-targeted therapies**



Cathepsin K Inhibitors

- Cathepsin K is a key enzyme responsible for osteoclastic bone resorption
- Expressed in tumors that commonly metastasize to bone (breast, prostate)
- Odanacatib
 - Phase II trial in women with MBC showed suppression of markers of bone resorption after 4 weeks of treatment
 - Few ongoing trials in patients with cancer to bone

Santini D, et al. *Cancer Treat Rev.* 2010; 36 Suppl 3:S6-S10;
<http://www.clinicaltrials.gov>. Accessed 3/1/11.

C-Src inhibitors

- Ubiquitously expressed nonreceptor tyrosine kinase
- Involved in signaling cascades important for receptor-mediated osteoclast formation and function
- Preclinical data show Src promotes bone metastases
- Currently being evaluated in clinical trials for patients with metastatic bone disease from solid tumors
 - Dasatinib

Santini D, et al. *Cancer Treat Rev.* 2010;36 Suppl 3:S6-S10;
<http://www.clinicaltrials.gov>. Accessed 3/1/11.

Conclusions

- Bone loss is a significant problem for patients with CTIBL or metastatic cancer to bone
- Bisphosphonates and more recently RANKL inhibitors:
 - Prevent bone loss in pts with CTIBL
 - Reduce SREs in pts with metastatic cancer to bone
- Adjuvant bisphosphonate use is still preliminary in patients with early stage breast cancer
- Ongoing clinical trials with novel agents for patients with metastatic breast and prostate cancers